Gamgee was founded by Paul Conyngham after he used AI (Grok) to help design a personalized mRNA cancer vaccine for his dog Rosie, which led to significant tumor shrinkage. The company focuses on producing personalized mRNA cancer vaccines for canine patients. Gamgee has raised a $4 million seed round led by Founders Fund to scale its vaccine-design and manufacturing processes. The announcement frames the funding as enabling the company to build personalized cancer treatments for dogs at scale. No revenue, user, or other operating metrics were disclosed in the reporting. Further details on additional investors, valuation, or founding year were not provided in the available articles.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2026